Colin Ng was previously the VP of Consumable and Process Development at IsoPlexis where he developed and launched a novel characterization technology that uncovered unique biological insights in cancer immunology, infectious disease and inflammation. He has expertise in developing assays in characterizing immune cell functionality and signal transduction. His department developed and patented new surface chemistries and applications in single-cell proteomics, metabolomics and transcriptomics that powered research over 50 academic and pharmaceutical institutions across the globe. Colin and his team investigated single cell functionality in a wide variety of applications including CAR-T, TCR-T, gene editing, bispecific antibodies, combination and checkpoint inhibitor therapies that led to publications and presentations in over 30 leading journals and conferences.